101 related articles for article (PubMed ID: 3311459)
1. Successful reversal of acute cardiac allograft rejection with OKT*3 monoclonal antibody.
Costanzo-Nordin MR; Silver MA; O'Connell JB; Pifarre R; Grady KL; Winters GL; Murdock DK; Sullivan HJ; Grieco JG; Scanlon PJ
Circulation; 1987 Nov; 76(5 Pt 2):V71-80. PubMed ID: 3311459
[TBL] [Abstract][Full Text] [Related]
2. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
4. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.
Costanzo MR; Koch DM; Fisher SG; Heroux AL; Kao WG; Johnson MR
J Heart Lung Transplant; 1997 Feb; 16(2):169-78. PubMed ID: 9059928
[TBL] [Abstract][Full Text] [Related]
5. Reversal of recalcitrant cardiac allograft rejection with methotrexate.
Costanzo-Nordin MR; Grusk BB; Silver MA; Sobotka PA; Winters GL; O'Connell JB; Pifarré R; Robinson JA
Circulation; 1988 Nov; 78(5 Pt 2):III47-57. PubMed ID: 3052918
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression induction with daclizumab and antithymocyte globulin in cardiac transplantation: clinical experience with 8 cases.
Huang XS; Chen DZ; Chen LW; Li ZQ; Liao CX
Di Yi Jun Yi Da Xue Xue Bao; 2004 Feb; 24(2):126-8. PubMed ID: 14965807
[TBL] [Abstract][Full Text] [Related]
7. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cardiac transplant rejection without massive immunosuppression.
Michler RE; Smith CR; Drusin RE; Reison DS; Hickey TJ; Lamb J; Reemtsma K; Rose EA
Circulation; 1986 Nov; 74(5 Pt 2):III68-71. PubMed ID: 3533317
[TBL] [Abstract][Full Text] [Related]
9. [OKT 3 treatment of kidney transplant recipients].
Zlabinger GJ; Ulrich W; Pohanka E; Kovarik J
Wien Klin Wochenschr; 1990 Mar; 102(5):142-7. PubMed ID: 2108521
[TBL] [Abstract][Full Text] [Related]
10. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
[TBL] [Abstract][Full Text] [Related]
12. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation.
Hooks MA; Wade CS; Millikan WJ
Pharmacotherapy; 1991; 11(1):26-37. PubMed ID: 1902291
[TBL] [Abstract][Full Text] [Related]
13. Effectivity of a T-cell-adapted induction therapy with anti-thymocyte globulin (Sangstat).
Koch A; Daniel V; Dengler TJ; Schnabel PA; Hagl S; Sack FU
J Heart Lung Transplant; 2005 Jun; 24(6):708-13. PubMed ID: 15949731
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 receptor blockade in cardiac transplantation: influence of HLA-DR locus incompatibility on treatment efficacy.
Lietz K; John R; Beniaminovitz A; Burke EM; Suciu-Foca N; Mancini DM; Edwards NM; Itescu S
Transplantation; 2003 Mar; 75(6):781-7. PubMed ID: 12660501
[TBL] [Abstract][Full Text] [Related]
15. OKT3 treatment of cardiac allograft rejection.
Haverty TP; Sanders M; Sheahan M
J Heart Lung Transplant; 1993; 12(4):591-8. PubMed ID: 8369321
[TBL] [Abstract][Full Text] [Related]
16. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
18. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
19. OKT3-induced hypotension in heart allograft recipients treated for steroid-resistant rejection.
Hosenpud JD; Norman DJ; Pantely GA; Cobanoglu AM; Starr A
J Heart Transplant; 1989; 8(2):159-65; discussion 165-6. PubMed ID: 2651620
[TBL] [Abstract][Full Text] [Related]
20. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3.
Kemnitz J; Cremer J; Schaefers HJ; Restrepo-Specht I; Haverich A; Uysal A; Heublein B; Wirth S
J Heart Lung Transplant; 1991; 10(3):366-72. PubMed ID: 1906746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
